MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
INKT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
MiNK Therapeutics, Inc.NASDAQ: INKT
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $2.85M rose 14.7% year over year, behind the +38.6% change in trailing-twelve-month operating expenses. Sequentially, it fell 12.1% from the prior quarter. Over 3 fiscal years it compounded at -26.4% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +14.7% toward the trailing-twelve-month pace of +38.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 12.31M USD
- Year-over-year change
- +17.9%
- 4-year CAGR
- -9.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.31M | +17.9% |
| FY2024 | 2024-12-31 | 10.43M | -54.1% |
| FY2023 | 2023-12-31 | 22.72M | -26.3% |
| FY2022 | 2022-12-31 | 30.83M | +66.4% |
| FY2021 | 2021-12-31 | 18.53M | — |
Operating Expenses vs competitors
How INKT compares with its peers on the latest reported figures
- INKT's LTM Mar 2026 operating expenses of $12.67M is the lowest of the 9 companies compared; the peer median is $33.76M.
- Its year-over-year change of +38.6% is the 3rd highest of 9, against a peer median of -12.7%.
- Over three fiscal years its annual growth of -26.4% compares with a peer median of -2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $59.37M | -22.3% | +2.5% | 17821.9% | |
| LTM Jun 2026 | $43.72M | -39.4% | -5.5% | 208.2% | |
| LTM Mar 2026 | $39.88M | +59.2% | +10.1% | 108.3% | |
| LTM Mar 2026 | $34.01M | -44.2% | -8.3% | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $33.51M | +199.7% | +85.4% | — |
| LTM Mar 2026 | $20.3M | -54.6% | -32.8% | — | |
| LTM Mar 2026 | $19.69M | -3.2% | +1.5% | — | |
| LTM Mar 2026 | $18.04M | +2.8% | -27.4% | 786.8% | |
| LTM Mar 2026 | $12.67M | +38.6% | -26.4% | — | |
| Peer median (excluding INKT) | $33.76M | -12.7% | -2.0% | 497.5% | |
Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| Gross Profit | (77.96K) | (121.75K) | (204.62K) | (215.44K) | (181.75K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.97M | 23.12M | 15.49M | 6.34M | 5.76B |
| Selling, General & Admin | 4.56M | 7.71M | 7.43M | 4.1M | 6.73B |
| Operating Expenses | 18.53M | 30.83M | 22.72M | 10.43M | 12.31M |
| Depreciation & Amortization | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| EBITDA | (27.7M) | (27.87M) | (22.25M) | (10.57M) | (12.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.61M) | (30.95M) | (22.92M) | (10.65M) | (12.49M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.43K | 253.32K | 463.26K | 172.57K | 180.25K |
| Interest Expense | 2.43M | 253.32K | 0 | 0 | 0 |
| Other Income / Expenses | (11.61M) | 2.96M | 463.25K | (134.56K) | (6.96K) |
| Income Before Tax | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.03) | (8.31) | (6.54) | (2.90) | (2.93) |
| EPS (Diluted) | (9.03) | (8.31) | (6.54) | (2.80) | (2.93) |
| Weighted Avg Shares | 3.35M | 3.37M | 3.44M | 3.74M | 4.27M |
| Weighted Avg Shares (Diluted) | 3.35M | 3.37M | 3.44M | 3.86M | 4.27M |
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.